Oral administration of Lactobacillus brevis 23017 combined with ellagic acid attenuates intestinal inflammatory injury caused by Eimeria infection by activating the Nrf2/HO-1 antioxidant pathway

Table 3 Body weight gain of the chickens in each group after challenge with E. tenella

Group	Survival rate (%)	Average body weight gain (g)	Relative body weight gain (%)
PBS	100	78.75 ± 2.46^a	100
Experiment 1
H/LB(+)	100	56.57 ± 3.85^b	71.83
M/LB(+)	100	53.68 ± 3.85^b	68.17
L/LB(+)	100	51.33 ± 3.27^b	65.18
H/LB(−) + E. tenella	100	51.73 ± 3.27^b	65.69
M/LB(−) + E. tenella	100	52.08 ± 2.94^b	66.13
L/LB(−) + E. tenella	100	51.67 ± 3.85^b	65.61
Experiment 2
H/EA + H/LB(+)	100	66.46 ± 3.85^b	84.39
M/EA + M/LB(+)	100	58.35 ± 3.85^b	74.10
L/EA + L/LB(+)	100	56.48 ± 3.85^b	71.72
Challenge control group	100	40.05 ± 2.65^c	50.86

Data represent the mean ± SD. Significant differences (p < 0.05) between two numbers in a column are indicated by different lowercase letters. After oral administration of L. brevis 23017 combined with EA, all chickens except those in the PBS group were challenged with E. tenella sporulated oocysts at 21 days of age.

ISSN: 1297-9716